Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 4018

Drug Profile

REGN 4018

Alternative Names: Anti MUC16-CD3 antibody; REGN4018

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Mucin inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 07 Jan 2019 Regeneron and Sanofi amend immuno-oncology collaboration agreement to narrow down its scope and agree to co-develop REGN 4018 for Cancer
  • 21 May 2018 Phase-I/II clinical trials in Fallopian tube cancer (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03564340)
  • 21 May 2018 Phase-I/II clinical trials in Fallopian tube cancer (Monotherapy, Second-line therapy or greater) in USA (IV) (NCT03564340)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top